GENENTECH, INC.
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Subsidiary
- Established
- 1976-01-01
- Employees
- 11.1K
- Market Cap
- -
- Website
- http://www.gene.com
A Study of the Safety, Tolerability, Pharmacokinetics, and Immunogenicity of Intravitreal Injections of FCFD4514S in Patients With Geographic Atrophy
- First Posted Date
- 2009-09-09
- Last Posted Date
- 2022-12-13
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 18
- Registration Number
- NCT00973011
A Study to Evaluate Lebrikizumab (MILR1444A) in Adult Patients With Asthma Who Are Not Taking Inhaled Corticosteroids
- First Posted Date
- 2009-09-03
- Last Posted Date
- 2016-11-29
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 210
- Registration Number
- NCT00971035
A Study of Hedgehog Pathway Inhibitor GDC-0449 in Patients With Locally Advanced or Metastatic Solid Tumors That Are Refractory to Standard Therapy or for Whom No Standard Therapy Exists
- First Posted Date
- 2009-08-31
- Last Posted Date
- 2017-07-11
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 67
- Registration Number
- NCT00968981
A Study to Evaluate the Efficacy and Safety of Rontalizumab in Patients With Moderately to Severely Active Systemic Lupus Erythematosus
- First Posted Date
- 2009-08-20
- Last Posted Date
- 2016-08-12
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 238
- Registration Number
- NCT00962832
A Study of PI3-Kinase Inhibitor GDC-0941 in Combination With Paclitaxel, With and Without Bevacizumab or Trastuzumab, and With Letrozole, in Participants With Locally Recurrent or Metastatic Breast Cancer
Phase 1
Completed
- Conditions
- Breast Cancer
- Interventions
- First Posted Date
- 2009-08-18
- Last Posted Date
- 2016-12-15
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 71
- Registration Number
- NCT00960960
A Study of Vismodegib (GDC-0449) in Patients Treated With Vismodegib in a Previous Genentech-sponsored Phase I or II Cancer Study
Phase 2
Completed
- Conditions
- Basal Cell CarcinomaMetastatic Colorectal CancerOvarian Cancer
- Interventions
- First Posted Date
- 2009-08-14
- Last Posted Date
- 2015-01-07
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 19
- Registration Number
- NCT00959647
A Study of MNRP1685A in Combination With Bevacizumab With or Without Paclitaxel in Patients With Locally Advanced or Metastatic Solid Tumors
Phase 1
Completed
- Conditions
- Solid Cancers
- Interventions
- First Posted Date
- 2009-08-07
- Last Posted Date
- 2017-05-17
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 24
- Registration Number
- NCT00954642
A Study of Trastuzumab Emtansine, Paclitaxel, and Pertuzumab in Patients With HER2-Positive, Locally Advanced or Metastatic Breast Cancer
Phase 1
Completed
- Conditions
- Metastatic Breast Cancer
- Interventions
- First Posted Date
- 2009-08-04
- Last Posted Date
- 2016-06-24
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 107
- Registration Number
- NCT00951665
Corrected QT Interval Effects of Trastuzumab Emtansine (T-DM1) in Patients With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Locally Advanced or Metastatic Breast Cancer and the Safety and Tolerability of Combined T-DM1 and Pertuzumab in Patients With Early Disease Progression
Phase 2
Completed
- Conditions
- Metastatic Breast Cancer
- Interventions
- Biological: pertuzumabBiological: Trastuzumab emtansine [Kadcyla]
- First Posted Date
- 2009-07-22
- Last Posted Date
- 2013-05-27
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 51
- Registration Number
- NCT00943670
A Study of Trastuzumab-MCC-DM1 Administered Intravenously to Patients With HER2-Positive Metastatic Breast Cancer Who Have Previously Received a Trastuzumab-Containing Regimen
- First Posted Date
- 2009-07-03
- Last Posted Date
- 2015-08-26
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 54
- Registration Number
- NCT00932373
© Copyright 2025. All Rights Reserved by MedPath